CTOR (Citius Oncology) OCF Margin %: -229.87% (As of Mar. 2026)


CTOR Citius Oncology Inc CTOR
10 GF Score
Price $0.66
! 2 Warning Signs
View Full Analysis

What is Citius Oncology OCF Margin %?

Citius Oncology CTOR 10 OCF Margin % is -229.87% as of Mar. 2026. GuruFocus rates CTOR with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 959 Drug Manufacturers companies, Citius Oncology ranks worse than 94.89% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Citius Oncology's Cash Flow from Operations for the three months ended in Mar. 2026 was $-3.83 Mil. Citius Oncology's Revenue for the three months ended in Mar. 2026 was $1.67 Mil. Therefore, Citius Oncology's OCF Margin % for the quarter that ended in Mar. 2026 was -229.87%.

As of today, Citius Oncology's current OCF Yield % is -18.23%.

The historical rank and industry rank for Citius Oncology's OCF Margin % or its related term are showing as below:

CTOR' s OCF Margin % Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0
Current: -199.38

CTOR's OCF Margin % is ranked worse than
94.89% of 959 companies
in the Drug Manufacturers industry
Industry Median: 9.95 vs CTOR: -199.38

Citius Oncology OCF Margin % Related Terms

Citius Oncology OCF Margin % Historical Data

* Premium members only.

The historical data trend for Citius Oncology's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citius Oncology OCF Margin % Chart

Citius Oncology Annual Data
Trend Sep22 Sep23 Sep24 Sep25
OCF Margin %
0.00 0.00 0.00 0.00

Citius Oncology Quarterly Data
Sep22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -186.49 -229.87

CTOR vs INCR, BGM, CPIX: OCF Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Citius Oncology OCF Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Citius Oncology's OCF Margin % falls into.


CTOR
10GF Score
Citius Oncology Inc CTOR
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Citius Oncology OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Citius Oncology's OCF Margin for the fiscal year that ended in Sep. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Sep. 2025 )/Revenue (A: Sep. 2025 )
=-5.492/0
= %

Citius Oncology's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-3.832/1.667
=-229.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -229.87% mean?
Citius Oncology (CTOR) has a OCF Margin % of -229.87% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Citius Oncology and its competitors. According to the industry distribution chart, Citius Oncology ranks #910 out of 959 companies in the Drug Manufacturers industry, placing it in the top 94.9%.
Is Citius Oncology's OCF Margin % too high?
Citius Oncology's current OCF Margin % is -229.87%. Based on the distribution chart, Citius Oncology ranks #910 out of 959 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Citius Oncology has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Citius Oncology's OCF Margin % compare to INCR and BGM?
According to the Drug Manufacturers industry distribution chart, Citius Oncology ranks #910 out of 959 companies for OCF Margin %. This places Citius Oncology in the lower half of its industry. The industry median OCF Margin % is 9.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.95, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Citius Oncology and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Citius Oncology's current OCF Margin % is -229.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Oncology stock overvalued right now?
Citius Oncology (CTOR) has a current OCF Margin % of -229.87%. The current OCF Margin % is -229.87%. Citius Oncology's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Citius Oncology (CTOR), the current OCF Margin % is -229.87% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Citius Oncology Business Description

Address 11 Commerce Drive, First Floor, Cranford, NY, USA, 07016
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
10GF Score

Get the complete analysis for CTOR

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.66
Price